GSK delivers strong 2023 performance and upgrades growth outlooks
For media and investors only
Issued: London, UK
Download
(PDF, 942.2KB)
Broad-based performance drives sales, profits and earnings growth:
Total 2023 sales £30.3 billion +5% and +14% ex COVID
Vaccines sales +25%, +24% ex COVID.
Shingrix
£3.4...
Zur Pressemeldung auf www.gsk.com